96It must be pointed out that Article 11 of Directive 65/65, which sets out the substantive criteria for the suspension and withdrawal of a marketing authorisation of a medicinal product, is intended to confer rights on undertakings which are holders of a marketing authorisation, since it protects those undertakings by ensuring that a decision to suspend or withdraw a marketing authorisation can only be adopted in certain specific conditions and by ensuring the retention of a marketing authorisation as long as the existence of one of those conditions is not established.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.